You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR LORATADINE AND PSEUDOEPHEDRINE SULFATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00837915 ↗ Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions Completed Ranbaxy Laboratories Limited N/A 2002-06-01 The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in a fully replicated design, under fasting conditions.
NCT00845546 ↗ Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions Completed Ranbaxy Laboratories Limited N/A 2002-06-01 The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in a fully replicated design, under fed conditions.
NCT01055756 ↗ Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis Withdrawn Azidus Brasil Phase 3 2010-01-01 The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.
NCT03443843 ↗ A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure Completed Bayer Phase 4 2018-02-21 The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.
NCT03517930 ↗ A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects Completed Bayer Phase 1 2018-04-17 To evaluate the bioequivalence of one extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by Schering-Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.
NCT03517943 ↗ A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects Completed Bayer Phase 1 2018-04-24 To evaluate the bioequivalence of one extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by Schering- Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Condition Name

Condition Name for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Intervention Trials
Clinical Pharmacology 2
Healthy 2
Allergic Rhinitis 1
Rhinitis, Allergic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Intervention Trials
Rhinitis, Allergic 2
Rhinitis 2
Malnutrition 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Trials by Country

Trials by Country for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Location Trials
Canada 3
United States 2
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Location Trials
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Clinical Trial Phase

Clinical Trial Phase for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 1 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Clinical Trial Phase Trials
Completed 5
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Sponsor Name

Sponsor Name for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Sponsor Trials
Bayer 3
Ranbaxy Laboratories Limited 2
Azidus Brasil 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.